A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

Inclusion Criteria: 1. Patients who meet the diagnosis of NASH. 2. Evidence of metabolic syndrome, except for those patients with biopsy-proven NASH. 3. Body mass index (BMI) \>25 kg/m2, NOTE: for Asian-Americans BMI \>23 kg/m2. 4. Stable use of other antidiabetic, weight loss, or lipid-modifying medications for at least 12 weeks prior to randomization. Exclusion Criteria: 1. Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days, whichever is longer. 2. Previous exposure to farnesoid X receptor (FXR) agonists 3 months prior to the first dosing. 3. Current or within 6 months of screening use of drugs associated with steatosis, including but not limited to eg, methotrexate, amiodarone, high-dose estrogen, tamoxifen, long term systemic steroids, anabolic steroids, valproic acid. 4. Prothrombin time international normalized ratio \>1.3, unless due to therapeutic anticoagulation. 5. Total bilirubin \>upper limit of normal (ULN; except for patients with Gilbert's syndrome with a normal direct bilirubin value and normal reticulocyte count). Platelet count \<140 000/mm³, absolute neutrophil count \<1500 cells/mm3, or total 6. white blood cells \<3000 cells/mm3. 7. Alanine aminotransferase and aspartate aminotransferase (AST) \>5 × ULN, or alkaline phosphatase (ALP) \>1.5 × ULN. 8. Weight changes \>10% in 6 months prior to screening, or weight changes \>5% from the screening MRI-PDFF to randomization or from the time of the diagnostic liver biopsy to randomization, whichever is longer. 9. Poorly controlled hypertension (systolic \>160 mm Hg, or diastolic blood pressure \>100 mm Hg - mean of 3 measurements). 10. Uncontrolled diabetes mellitus (hemoglobin A1c \>10.0% during screening).